Showing 1431-1440 of 1550 results for "".
- Monkeypox Update: Kids Aged 8 or Younger at High Risk for More Severe Monkeypoxhttps://practicaldermatology.com/news/monkey-pox-update-kids-aged-8-or-younger-at-high-risk-for-more-severe-monkeypox/2461409/Children aged 8 years or younger are at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal. Young children would be a key target group for smallpox vaccination and other urgent measures if the outbreak widens, according to the review b
- Industry Vet Curtis Cluff Named President and CFO of BioPhotas Inc.https://practicaldermatology.com/news/industry-vet-curtis-cluff-named-president-and-cfo-of-biophotas-inc/2461378/Curtis Cluff is the new President and Chief Financial Officer BioPhotas Inc., manufacturers of the Celluma series of light therapy devices. In this newly created role, Mr. Cluff will report to Patrick Johnson, Chief Executive Officer and inventor of the Celluma. &quo
- Study: Galderma's RelabotulinumtoxinA Earns High Marks from Patientshttps://practicaldermatology.com/news/study-galdermas-relabotulinumtoxina-earns-high-marks-from-patients/2461377/Galderma's investigational ready-to-use liquid botulinum toxin RelabotulinumtoxinA scored high patient satisfaction and psychological well-being ratings for the treatment of glabellar lines and lateral canthal lines in addition to previously reported safety and efficacy, according to pre
- Cutera: Aviclear Hits 1,000 Treatment Markhttps://practicaldermatology.com/news/cutera-aviclear-hits-1000-treatment-mark/2461333/More than 1,000 AviClear laser acne treatments have been performed in the United States, Cutera reports. AviClear is FDA-cleared for the treatment of mild, moderate and severe acne. Additionally, AviClear recently received approval from Health Canada for the treatment of all severities
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCChttps://practicaldermatology.com/news/sirnaomics-achieves-100-complete-response-in-phase-ii-clinical-trial-of-stp705-for-treatment-of-cutaneous-bcc/2461319/Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports. STP705 is a siRNA (small inte
- First Patient Dosed in Phase 1b/2 Trial of Dermaliq Therapeutics's DLQ02 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-1b2-trial-of-dermaliq-therapeuticss-dlq02-for-pso/2461310/The first patient has been dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor, Dermaliq Therapeutics, Inc. reports. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaqu
- Alma Launches the Alma Hybrid and Alma TED Systems in Canadahttps://practicaldermatology.com/news/alma-launches-the-alma-hybrid-and-alma-ted-systems-in-canada/2461298/Alma Hybrid and Alma TED systems are now commercially available in Canada, the company reports. Alma Hybrid, the first laser platform to include an ablative 10,600 nm (CO2) laser and a non-ablative 1570 nm laser for skin resurfacing that offers a comprehensive solution to utilize each b
- NRS Survey: Persistent Facial Redness Named Most Common and Bothersome Sign of Rosaceahttps://practicaldermatology.com/news/nrs-survey-persistent-facial-redness-is-the-most-common-and-bothersome-sign-of-rosacea/2461285/The great majority of rosacea patients have experienced persistent facial redness, and most of them report it is the most frequently bothersome sign they face, according to a recent National Rosacea Society (NRS) survey on rosacea redness sponsored by EPI Health. Furthermore, two-
- New Crystal Ball Predictions Released by Allergan Aestheticshttps://practicaldermatology.com/news/new-crystal-ball-predictions-released-by-allergan-aesthetics/2461238/Consumer interest in medical aesthetics continues to rise, with the number of dermal filler treatments worldwide growing by almost two million between 2017 and 2020, according to Allergan Aesthetics’ 'The Future of Aesthetics' global trends report. In addition, the r
- Arcutis Completes Enrollment in Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasishttps://practicaldermatology.com/news/arcutis-completes-enrollment-in-phase-3-trial-of-topical-roflumilast-foam-in-scalp-and-body-psoriasis/2461153/Enrollment in Arcutis’ ARRECTOR pivotal Phase 3 trial of topical roflumilast foam in adolescents and adults with scalp and body psoriasis is complete, the company reported. Roflumilast foam is a once-daily, topical formulation of a highly potent and selective phosphodiesterase-4 (